Tag - CARA

Developments

FDA clears Vifor, Cara pruritus injection associated with CKD

The FDA approved an NDA from Vifor Pharma and Cara Therapeutics (NASDAQ:CARA) for their KORSUVA injection for the treatment of moderate-to-severe pruritus (itch) associated with chronic kidney disease in adults...

August 24, 2021

Developments

Cara Therapeutics completes enrollment in Phase 2 pruritis trial

Cara Therapeutics (NASDAQ:CARA) completed enrollment in its Phase 2 KARE trial evaluating KORSUVA for the treatment of moderate-to-severe pruritus, or itchy skin, in atopic dermatitis patients. The trial enrolled 400...

December 2, 2020

Tag - CARA

FDA clears Vifor, Cara pruritus injection associated with CKD

Cara Therapeutics completes enrollment in Phase 2 pruritis trial

General

More